China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...

The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated ...

The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of ...

Poxel is a biopharmaceutical company developing drugs for metabolic diseases, with a focus on type 2 diabetes. Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono. Poxel is focsed on ...

The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...